Acrivon Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.3%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$2.07next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly97.7MTarget: Sufficient to fund operations into Q3 2027
Confirmed Overall Response Rate (cORR) in Serous Endometrial Cancer Annually52.0%Target: Maintain high efficacy in registrational-intent Phase 2b study
Quarterly Net Loss Quarterly-19MTarget: Controlled cash burn through disciplined expense management
Watch Items
- ACR-368 Phase 2b simultaneous interim analysis and data updateTrigger: Second Half of 2026Action: Evaluate objective response rates and safety profiles in biopsy-independent serous endometrial cancer arms (Arms 3 and 4).
- ACR-2316 Phase 1/2 trial dose expansionTrigger: Transition from dose-escalation to expansion phaseAction: Monitor safety (specifically transient neutropenia) and clinical activity in AP3-prioritized solid tumors, including lung cancers.
- ACR-6840 IND filingTrigger: Fourth Quarter of 2026Action: Verify submission of the Investigational New Drug application for the CDK11 inhibitor candidate.
Research as of 19 Jun 2026